TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02378896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Computer Program
Description: Training with a personalized computerized inhibitory training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
Study: NCT02752503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Study: NCT02094807

Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Will be used if other drugs are not tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Will be used if other drugs are not tolerated.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: thoracic epidural anesthesia
Description: Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural anesthesia
Description: Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.

Intervention type: DRUG
Group type: OTHER
Intervention: opioids
Description: During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioids
Description: During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol
Description: 100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative fixation of rib fractures
Description: Fractures will be stabilized on the outside of of the ribs.
Study: NCT04083664

Intervention type: DIAGNOSTIC_TEST
Intervention: NGAL and Hepcidin
Description: Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia

Intervention type: DIAGNOSTIC_TEST
Intervention: NGAL and Hepcidin
Description: Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia

Intervention type: DIAGNOSTIC_TEST
Intervention: NGAL and Hepcidin
Description: Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
Study: NCT04580316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental active presence
Description: The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent passive presence
Description: Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
Study: NCT04659018

Intervention type: BIOLOGICAL
Intervention: blood collection
Description: A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
Study: NCT03081611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ram cannula
Description: Ventilatory support for preterm infants using Ram cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short nasal prongs
Description: Ventilatory support for preterm infants using short nasal prongs
Study: NCT02937532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + TOBT training
Description: All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
Study: NCT04629768

Intervention type: DEVICE
Group type: OTHER
Intervention: PuraStat
Description: Purastat is applied to the EMR defect
Study: NCT04124666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocytes
Description: Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
Study: NCT03876977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic laparoscopic decompression of pudendal nerve entrapment
Description: Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance
Study: NCT04842136

Intervention type: OTHER
Intervention: Scales and indexes
Description: Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.

Intervention type: OTHER
Intervention: Scales and indexes
Description: Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
Study: NCT03055442

Intervention type: OTHER
Intervention: Dosage of myo-inositol
Description: Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)

Intervention type: OTHER
Intervention: Dosage of D-chiro-inositol
Description: Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
Study: NCT01200264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apremilast
Description: apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
Study: NCT04572126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
Study: NCT02503020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm infants formula A
Description: Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm infants formula B
Description: Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age.
Study: NCT02099695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The quantity of tablets will increase due to the absence/ lack of therapeutic response.
Study: NCT03053219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
Study: NCT00833742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Short-term Dynamic Psychotherapy
Description: A brief psychotherapy format
Study: NCT01732484

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraocular lens implantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraocular lens implantation
Study: NCT01513564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative epidural morphine
Description: The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Description: Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
Study: NCT00697684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
Study: NCT04943419

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Myeloid-Derived Suppressor Cells
Description: Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
Study: NCT02247817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid CRT-D/P implantation
Study: NCT00697684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
Study: NCT04370951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block - Ultrasound guided
Description: 20mls 0.25% Levobupivicaine ultrasound guided bilaterally
Study: NCT00774696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin 500mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin 500mg tablets
Study: NCT03880799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Session
Description: one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
Study: NCT03561441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored aggressive hydration
Description: 1. Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tailored standard hydration
Description: 1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked.
Study: NCT02813057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stoppa inguinal hernia repair
Description: Stoppa inguinal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total extraperitoneal inguinal hernia repair
Description: Total extraperitoneal inguinal hernia repair
Study: NCT01681602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
Study: NCT00856973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day for 12 weeks
Study: NCT02969941

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.
Study: NCT01019863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
Study: NCT00302081

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 1.5 mcg/kg QW SC for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 1.0 mcg/kg QW SC for 24 weeks
Study: NCT01559064

Intervention type: DEVICE
Intervention: Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)
Description: All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.

Intervention type: DEVICE
Intervention: Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)
Description: All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.

Intervention type: DEVICE
Intervention: Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)
Description: All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
Study: NCT03801356

Intervention type: DRUG
Group type: OTHER
Intervention: Selective Nerve Root Block
Description: Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
Study: NCT01703611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MNT according to AND EBNPG for Type 2 DM
Description: Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
Study: NCT00302081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 1.5 mcg/kg QW SC for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (SCH 18908)
Description: 800-1200 mg daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin (SCH 18908)
Description: 800-1200 mg daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (SCH 18908)
Description: 800-1200 mg daily for 16 weeks
Study: NCT03733210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: 30 mg administered intravenously (IV)
Study: NCT01703611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Nutrition Care
Description: Usual nutrition care in India
Study: NCT03733210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: 30 mg administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89-Zirconium (Zr-89) Panitumumab
Description: 0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89-Zirconium (Zr-89) Panitumumab
Description: 0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinpoint IR IR9000 fluorescence imaging system (FIS)
Description: Handheld fluorescence-imaging endoscope manufactured by Novadaq

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinpoint IR IR9000 fluorescence imaging system (FIS)
Description: Handheld fluorescence-imaging endoscope manufactured by Novadaq

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY-PHI IR9000 fluorescence imaging system (FIS)
Description: Handheld fluorescence-imaging endoscope manufactured by Novadaq
Study: NCT02308761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
Study: NCT03368066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin
Description: Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
Study: NCT03733210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY-PHI IR9000 fluorescence imaging system (FIS)
Description: Handheld fluorescence-imaging endoscope manufactured by Novadaq

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Air camera
Description: Fluorescence camera manufactured by SurgVision